Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Sio Gene Therapies Inc. | axovantexhibit322.htm |
| EX-32.1 - EXHIBIT 32.1 - Sio Gene Therapies Inc. | axovantexhibit321.htm |
| EX-31.2 - EXHIBIT 31.2 - Sio Gene Therapies Inc. | axovantexhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 - Sio Gene Therapies Inc. | axovantexhibit311.htm |
| EX-23.2 - EXHIBIT 23.2 - Sio Gene Therapies Inc. | axovantexhibit232.htm |
| EX-21.1 - EXHIBIT 21.1 - Sio Gene Therapies Inc. | axovantexhibit211.htm |
| EX-10.15 - EXHIBIT 10.15 - Sio Gene Therapies Inc. | axovantexhibit1015.htm |
| EX-10.13 - EXHIBIT 10.13 - Sio Gene Therapies Inc. | axovantexhibit1013.htm |
| EX-10.12 - EXHIBIT 10.12 - Sio Gene Therapies Inc. | axovantexhibit1012.htm |
| 10-K - 10-K - Sio Gene Therapies Inc. | axovant3311710k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-8 No. 333-206300) pertaining to the 2015 Equity Incentive Plan,
(2) Registration Statement (Form S-8 No. 333-215386) pertaining to the 2015 Equity Incentive Plan, and
(3) Registration Statement (Form S-3 No. 333-215387) of Axovant Sciences Ltd.;
of our report dated June 13, 2017, with respect to the consolidated financial statements of Axovant Sciences Ltd. included in this Annual Report (Form 10-K) of Axovant Sciences Ltd. for the year ended March 31, 2017.
/s/ Ernst & Young LLP
Iselin, NJ
June 13, 2017
1